Modulation of the inflammatory response in the cardiomyocyte and macrophage

Journal of Extra-Corporeal Technology

Volumn 33, Issue 3, 2001, Pages 167-174

  Sanders, D B ^a   Hunter, K ^a   Wu, Y ^a   Jablonowski, C ^a   Bahl, J J ^a   Larson, D F ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac myocyte; Dexamethasone; Inducible nitric oxide synthase; Lipopolysaccharide; Macrophage; Nitric oxide; Tumor necrosis factor

Indexed keywords

CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; CARDIOMYOPATHY; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CONTROLLED STUDY; DEVICE; ENZYME INHIBITION; FETUS; FLUORESCENCE ACTIVATED CELL SORTER; GRAFT REJECTION; HEART MUSCLE CELL; INFLAMMATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; RAT; REPERFUSION INJURY; SPECTROPHOTOMETRY; STATISTICAL ANALYSIS;

EID: 0034785328     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Cytokines in myocardial injury: Impact on cardiac surgical approach
2. Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass
3. Alterations in the number of circulating leucocytes, phenotype of monocyte and cytokine production in patients undergoing cardiothoracic surgery
4. Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass
5. Platelet activation and cytokine production during hypothermic cardiopulmonary bypass - A possible correlation?
6. Cardiopulmonary bypass-induced inflammation: Is it important?
7. Interindividual variations in cytokine levels following cardiopulmonary bypass
8. Alterations of the cytokine network in patients undergoing cardiopulmonary bypass
9. Circulating endotoxin and cytokines after cardiopulmonary bypass: Differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes
10. The inflammatory response to cardiopulmonary bypass
11. Inflammatory response to cardiopulmonary bypass: Mechanisms involved and possible therapeutic strategies
12. The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations
13. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
14. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy
15. Cytokine regulation of chronic cardiac allograft rejection: Evidence against a role for Th1 in the disease process
16. The role of cytokines, CTLA-4 and co-stimulation in transplant tolerance and rejection
17. Intragraft cytokine gene expression: Implications for clinical transplantation
18. Cytokine expression during orthotopic corneal allograft rejection in mice
19. Possible role of proinflammatory cytokines in heart allograft coronary artery disease
20. Cytotoxic T lymphocytes and cytokines in graft vascular disease after clinical heart transplantation
21. Role of cytokines and cytokine-producing cells in reperfusion injury to the liver
22. Cytokines and the microcirculation in ischemia and reperfusion
23. Age-related alteration of cytokine production profile by T cell subsets in mice: A flow cytometric study
24. Altered cytokine production in the elderly
25. Perioperative cytokine release during coronary artery bypass grafting in patients of different ages
26. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure
27. Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy
28. CNI-1493 prolongs survival and reduces myocyte loss, apoptosis, and inflammation during rat cardiac allograft rejection
29. Time course and cellular localization of inducible nitric oxide synthases expression during cardiac allograft rejection
30. The role of inducible nitric oxide synthase in cardiac allograft rejection
31. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection
32. Inducible nitric oxide synthase is upregulated in human transplant coronary artery disease
33. Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure
34. The role of nitric oxide in heart failure
35. Attenuation of renal ischemia-reperfusion injury in inducible nitric oxide synthase knockout mice
36. Use of brain slices in the study of pathogenic role of inducible nitric oxide synthase in cerebral ischemia-reperfusion
37. Beneficial effects of inducible nitric oxide synthase inhibitor on reperfusion injury in the pig liver
38. Intestinal reperfusion-induced pulmonary edema is related to increased pulmonary inducible nitric oxide synthase activity
39. Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase
40. Aminoguanidine inhibits inducible NOS and reverses cardiac dysfunction late after ischemia and reperfusion - Implications for iNOS-mediated myocardial stunning
41. Inhibition of nitric oxide synthesis improves left ventricular contractility in neonatal pigs late after cardiopulmonary bypass
42. Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by s-nitrosoglutathione
43. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass
44. Differential expression of inducible nitric oxide synthase in septic shock
45. LPS-binding proteins and receptors
46. Activation of multiple proline-directed kinases by bacterial lipopolysaccharide in murine macrophages
47. Interleukin-1 regulates casein kinase II-mediated phosphorylation of the p65 subunit of NF-κB
48. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions
49. MEK kinase is involved in tumor necrosis factor α-induced NF-κB activation and degradation of IκB-α
50. Regulation of the human TNF promoter by the transcription factor Ets
51. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B
52. Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells
53. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-κB-dependent mechanism
54. Glucocorticoids suppress TNF-α expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-κB and c-Jun/ATF2 binding sites in the promoter
55. Antenatal dexamethasone suppresses tumor necrosis factor-alpha expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats
56. Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by glucocorticoids
57. Glucocorticoid receptor-mediated postceramide inhibition of the interleukin-1β-dependent induction of ovarian prostaglandin endoperoxide synthase-2 in rats
58. A negative regulatory region containing a glucocorticosteroid response element (nGRE) in the human interleukin-1β gene
59. Mechanism for dexamethasone inhibition of neutrophil migration upon exposure to lipopolysaccharide in vitro: Role of neutrophil interleukin-8 release
60. Grain dust induces IL-8 production from bronchial epithelial cells: The effect of dexamethasone on IL-8 production
61. Expression of interleukin-16 by human epithelial cells. Inhibition by dexamethasone
62. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism
63. Glucocorticoid reduction of bronchial epithelial inflammation during cardiopulmonary bypass
64. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans
65. Beneficial effects of methylprednisolone in patients on cardiopulmonary bypass